PDF(Pubmed)
Abstract：
Adenoid cystic carcinoma (ACC) is an uncommon and aggressive head and neck cancer mainly affecting minor salivary glands. It affects more women than men in their 60s and 70s. The tumor is typically locally aggressive and has a high rate of distant metastatic disease. This report unveils a potential avenue for targeted therapy for the management of metastatic disease: a patient with ACC who harbored a specific fibroblast growth factor receptor 2 (FGFR-2) mutation and responded significantly to a novel FGFR-2 inhibitor. This finding could pave the way for personalized treatment options for ACC patients with similar genetic alterations. Nevertheless, the use of futibatinib requires further investigation to optimize treatment protocols, including exploring combination therapies, identifying predictive biomarkers for treatment response, and developing strategies to overcome potential resistance.
摘要：
腺样囊性癌（ACC）是一种罕见且侵袭性的头颈部癌，主要影响小唾液腺。在60年代和70年代，它对女性的影响要多于男性。肿瘤通常是局部侵袭性的,并且具有高的远处转移性疾病的发生率。该报告揭示了靶向治疗转移性疾病的潜在途径：ACC患者具有特定的成纤维细胞生长因子受体2（FGFR-2）突变，并对新型FGFR-2抑制剂产生了显着反应。这一发现可以为具有相似遗传改变的ACC患者的个性化治疗方案铺平道路。然而，使用futibatinib需要进一步研究以优化治疗方案，包括探索联合疗法，确定治疗反应的预测性生物标志物，并制定克服潜在阻力的策略。
